504 related articles for article (PubMed ID: 32828424)
1. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
[TBL] [Abstract][Full Text] [Related]
2. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
3. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
5. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
6. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
10. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
Sobh EA; Khalil NA; Faggal SI; Hassan MSA
Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
[TBL] [Abstract][Full Text] [Related]
11. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.
Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A
Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910
[TBL] [Abstract][Full Text] [Related]
13. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
Akhtar MJ; Siddiqui AA; Khan AA; Ali Z; Dewangan RP; Pasha S; Yar MS
Eur J Med Chem; 2017 Jan; 126():853-869. PubMed ID: 27987485
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.
Abbas HS; Abd El-Karim SS
Bioorg Chem; 2019 Aug; 89():103035. PubMed ID: 31200286
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
20. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]